This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aronowski, J. Articles by Kontos, H. A. Search for Related Content PubMed PubMed Citation Articles by Aronowski, J. Articles by Kontos, H. A.

(Stroke. 1996;27:1571-1577.)
© 1996 American Heart Association, Inc.

Articles

Combined Neuroprotection and Reperfusion Therapy for Stroke

Effect of Lubeluzole and Diaspirin Cross-Linked Hemoglobin in Experimental Focal Ischemia

J. Aronowski, PhD; R. Strong, MS J.C. Grotta, MD

the Department of Neurology, The University of Texas Medical School, Houston, Tex.

Correspondence to Dr James C. Grotta, Department of Neurology, University of Texas Medical School, 6431 Fannin, Rm 7.044, Houston, TX 77030.

Background and Purpose In search of a better treatment for acute ischemic stroke, we evaluated the use of lubeluzole and hemodilution with diaspirin cross-linked hemoglobin (DCLHb) therapy to test whether treatment with two complementary acting compounds provides more potent protection than either treatment alone.

Methods We used unilateral reversible middle cerebral artery (MCA) and common carotid artery (CCA) occlusion of various durations in Long-Evans rats to produce ischemic cortical lesions. We calculated the average maximal lesion volume (Vol_max) and the time required to produce half maximal lesion size (T₅₀) in control animals (n=31) and evaluated the effects on cerebral perfusion and infarct size of treatment with lubeluzole (n=23), hemodilution (to 30% hematocrit) with albumin (n=17) or DCLHb (n=23), and combined lubeluzole+DCLHb therapy initiated 15 minutes after MCA/CCA occlusion.

Results The Vol_max produced by MCA/CCA occlusion in control animals was 138.5±7.7 mm³, and T₅₀ was 98.5±10.2 minutes. Lubeluzole alone reduced Vol_max by 53% with no significant effect on T₅₀. In contrast to lubeluzole, DCLHb hemodilution prolonged T₅₀ by 68% with no significant effect on Vol_max. Prolongation of T₅₀ by DCLHb was not due to hemodilution itself, since a similar degree of hemodilution with albumin had no effect. Finally, combined lubeluzole+DCLHb rescued 72% of the tissue and augmented the effect of lubeluzole alone by 40% (Vol_max, 66.3±13.0 versus 39.4±12.2 mm³) while prolonging T₅₀ by 31%.

Conclusions Combination therapy for acute stroke using compounds with complementary action can result in more complete attenuation of neuronal damage and demonstrates the possible clinical utility of combined neuroprotective and reperfusion therapies.

Editorial Comment

Effect of Lubeluzole and Diaspirin Cross-Linked Hemoglobin in Experimental Focal Ischemia

Hermes A. Kontos, MD

School of MedicineMedical College of VirginiaRichmond, Va

This article has been cited by other articles:

				M. Nemoto, T. Mito, W. S Brinigar, C. Fronticelli, and R. C. Koehler Salvage of focal cerebral ischemic damage by transfusion of high O2-affinity recombinant hemoglobin polymers in mouse J Appl Physiol, May 1, 2006; 100(5): 1688 - 1691. [Abstract] [Full Text] [PDF]

				M. Fisher, A. Davalos, A. Rogalewski, A. Schneider, E. B. Ringelstein, and W.-R. Schabitz Toward a Multimodal Neuroprotective Treatment of Stroke Stroke, April 1, 2006; 37(4): 1129 - 1136. [Abstract] [Full Text] [PDF]

				S. JONAS, V. AIYAGARI, D. VIEIRA, and M. FIGUEROA The Failure of Neuronal Protective Agents Versus the Success of Thrombolysis in the Treatment of Ischemic Stroke: The Predictive Value of Animal Models Ann. N.Y. Acad. Sci., June 1, 2001; 939(1): 257 - 267. [Abstract] [Full Text] [PDF]

				G. C. PALMER, J. PEELING, D. CORBETT, M. R. DEL BIGIO, and T. J. HUDZIK T2-Weighted MRI Correlates with Long-Term Histopathology, Neurology Scores, and Skilled Motor Behavior in a Rat Stroke Model Ann. N.Y. Acad. Sci., June 1, 2001; 939(1): 283 - 296. [Abstract] [Full Text] [PDF]

				P.-E. Chabrier, M. Auguet, B. Spinnewyn, S. Auvin, S. Cornet, C. Demerle-Pallardy, C. Guilmard-Favre, J.-G. Marin, B. Pignol, V. Gillard-Roubert, et al. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: A promising neuroprotective strategy PNAS, September 14, 1999; 96(19): 10824 - 10829. [Abstract] [Full Text] [PDF]

				H. P. Grocott, R. D. Bart, H. Sheng, Y. Miura, R. Steffen, R. D. Pearlstein, D. S. Warner, and E. P. Wei Effects of a Synthetic Allosteric Modifier of Hemoglobin Oxygen Affinity on Outcome From Global Cerebral Ischemia in the Rat • Editorial Comment Stroke, August 1, 1998; 29(8): 1650 - 1655. [Abstract] [Full Text] [PDF]

				R. Marrannes, E. D. Prins, and G. Clincke Influence of Lubeluzole on Voltage-Sensitive Ca++ Channels in Isolated Rat Neurons J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 201 - 214. [Abstract] [Full Text]

				M. Haseldonckx, J. Van Reempts, M. Van de Ven, L. Wouters, M. Borgers, and J. A. Clemens Protection With Lubeluzole Against Delayed Ischemic Brain Damage in Rats: A Quantitative Histopathologic Study Stroke, February 1, 1997; 28(2): 428 - 432. [Abstract] [Full Text]

				A. Rebel, J. A. Ulatowski, K. Joung, E. Bucci, R. J. Traystman, and R. C. Koehler Regional cerebral blood flow in cats with cross-linked hemoglobin transfusion during focal cerebral ischemia Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H832 - H841. [Abstract] [Full Text] [PDF]